About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
aRCC: 1L Treatment Options and Patient Management
aRCC: 1L Treatment Options and Patient Management
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
How I Manage Immune Adverse Events in Solid Tumors
By
Balazs Halmos
4 Videos
1,878 views
December 13, 2022
0 Comments
Login to view comments.
Click here to Login
aRCC: 1L Treatment Options and Patient Management
12:14
ASCO Genitourinary Cancers Symposium
ASCO GU 2022 Update on CheckMate 214 With Extended 5-Year Follow-Up:…
Feat.
S. Tykodi
08:40
Thomas Hutson
Overview of CheckMate 214: 5-Year Data on Nivo+Ipi in Patients With …
16:00
ASCO Genitourinary Cancers Symposium
ASCO GU 2022 Germline Mutations of Interests in Renal Cell Carcinoma
Feat.
M. Dean
09:23
ASCO Genitourinary Cancers Symposium
ASCO GU 2022 on Molecular Alterations Across Sites of Metastasis in …
Feat.
R. McKay
16:34
ASCO Genitourinary Cancers Symposium
ASCO GU 2022 Highlights on Adjuvant and Consolidative Therapy in Oli…
Feat.
N. Haas
06:04
ASCO 2022 Conference Coverage
ASCO 2022 on Safety & Clinical Activity of MEDI5752, a PD-1/CTLA…
Feat.
L. Albiges
47:32
Moffitt Cancer Center
Mechanisms of Resistance and Toxicity to Immune Checkpoint Therapy i…
Feat.
J. Gao
13:28
Total Health
2022 ASCO Renal Cell Carcinoma Updates
Feat.
M. Bupathi
12:53
O'Neal Comprehensive Cancer Center at UAB
Dual Immunotherapy in RCC
Feat.
A. Basu
20:47
ecancer
ESMO 2022 on the Latest in mRCC
Feat.
J. Puente,
B. Escudier,
V. Grünwald,
S. Oudard
21:09
Mário Fontes-Sousa
Evolving Landscape of 1L Systemic Treatment in Metastatic Renal Cell…
20:23
Aly-Khan A. Lalani
Choosing Wisely: 1L Combination Treatment for Advanced RCC
06:50
ecancer
ESMO 2022 Updates in Renal Cancer
Feat.
T. Choueiri
19:41
Balazs Halmos
How I Manage Immune Adverse Events in Solid Tumors
10:55
Yale Cancer Center
Systemic Therapies for Clear Cell RCC: Where Are We Now?
Feat.
D. Braun
14:14
PrecisCa
GU Tumor Board: 61 y/o Male With mRCC With Disease Progression After…
Feat.
M. Rettig,
S. Slovin,
T. Fraum,
J. Abel,
P. Patel